Ken Griffin Larimar Therapeutics, Inc. Transaction History
Citadel Advisors LLC
- $483 Billion
- Q2 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Larimar Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 36,500 shares of LRMR stock, worth $265,355. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36,500
Previous 108,700
66.42%
Holding current value
$265,355
Previous $825,000
68.0%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding LRMR
# of Institutions
111Shares Held
68MCall Options Held
290KPut Options Held
38.9K-
Deerfield Management Company, L.P. (Series C) New York, NY21.2MShares$154 Million3.23% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.05MShares$43.9 Million0.66% of portfolio
-
Janus Henderson Group PLC London, X04.38MShares$31.8 Million0.02% of portfolio
-
Goldman Sachs Group Inc New York, NY4.33MShares$31.5 Million0.01% of portfolio
-
Blue Owl Capital Holdings LP New York, NY3.86MShares$28.1 Million11.62% of portfolio
About Larimar Therapeutics, Inc.
- Ticker LRMR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,269,200
- Market Cap $315M
- Description
- Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. T...